Amgen Rebuilt R&D Platform To Focus On Speed And Access
Genetics, AI And Other Tools Assembled Over Past Decade
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
